LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,223
تعداد مقالات11,156
تعداد مشاهده مقاله76,807,231
تعداد دریافت فایل اصل مقاله101,043,416
Negahdaripour, Manica. (1404). The Future of mRNA Platforms: Strategic Pause or Premature Pivot?. سامانه مدیریت نشریات علمی, 50(10), 658-660. doi: 10.30476/ijms.2025.108672.4367
Manica Negahdaripour. "The Future of mRNA Platforms: Strategic Pause or Premature Pivot?". سامانه مدیریت نشریات علمی, 50, 10, 1404, 658-660. doi: 10.30476/ijms.2025.108672.4367
Negahdaripour, Manica. (1404). 'The Future of mRNA Platforms: Strategic Pause or Premature Pivot?', سامانه مدیریت نشریات علمی, 50(10), pp. 658-660. doi: 10.30476/ijms.2025.108672.4367
Negahdaripour, Manica. The Future of mRNA Platforms: Strategic Pause or Premature Pivot?. سامانه مدیریت نشریات علمی, 1404; 50(10): 658-660. doi: 10.30476/ijms.2025.108672.4367

The Future of mRNA Platforms: Strategic Pause or Premature Pivot?

Iranian Journal of Medical Sciences
مقاله 1، دوره 50، شماره 10، دی 2025، صفحه 658-660    اصل مقاله (178.13 K)
نوع مقاله: Editorial
شناسه دیجیتال (DOI): 10.30476/ijms.2025.108672.4367
نویسنده
Manica Negahdaripour* 1، 2، 3
1Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Artificial Intelligence, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
The last month’s decision by the U.S. Department of Health and Human Services (HHS) to withdraw nearly $500 million from mRNA vaccine research and development (R&D) has aroused concern in the scientific and medical communities.

تازه های تحقیق

Manica Negahdaripour (Google Scholar)

کلیدواژه‌ها
Vaccines؛ Messenger RNA؛ Vaccine development؛ COVID-19 vaccines؛ Public health policy
مراجع
  1. Health Services DH [Internet].HHS Winds Down mRNA Vaccine Development Under BARDA. [cited 2 Sept. 2025]. Available from: https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html
  2. Mohammadi Y, Nezafat N, Negahdaripour M, Eskandari S, Zamani M. In silico design and evaluation of a novel mRNA vaccine against BK virus: a reverse vaccinology approach. Immunol Res. 2023;71:422-41. doi: 10.1007/s12026-022-09351-3. PubMed PMID: 36580228; PubMed Central PMCID: PMCPMC9797904.
  3. Negahdaripour M, Ghasemi Y. Witnessing a revolution in the vaccinology field: A thought on its probable impact on future vaccines. Trends in Pharmaceutical Sciences and Technologies. 2022;8:67-8.
  4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-15. doi: 10.1056/NEJMoa2034577. PubMed PMID: 33301246; PubMed Central PMCID: PMCPMC7745181.
  5. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403-16. doi: 10.1056/NEJMoa2035389. PubMed PMID: 33378609; PubMed Central PMCID: PMCPMC7787219.
  6. Wong BK, Mabbott NA. Systematic review and meta-analysis of COVID-19 mRNA vaccine effectiveness against hospitalizations in adults. Immunother Adv. 2024;4:11. doi: 10.1093/immadv/ltae011. PubMed PMID: 39703784; PubMed Central PMCID: PMCPMC11655844.
  7. Hansen CH, Lassauniere R, Rasmussen M, Moustsen-Helms IR, Valentiner-Branth P. Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study. Lancet Infect Dis. 2025. doi: 10.1016/S1473-3099(25)00380-9. PubMed PMID: 40749700.
  8. Stowe J, Miller E, Andrews N, Whitaker HJ. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England. PLoS Med. 2023;20:e1004245. doi: 10.1371/journal.pmed.1004245. PubMed PMID: 37285378; PubMed Central PMCID: PMCPMC10286992.
  9. Wu X, Xu K, Zhan P, Liu H, Zhang F, Song Y, et al. Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis. BMC Infect Dis. 2024;24:234. doi: 10.1186/s12879-023-08754-3. PubMed PMID: 38383356; PubMed Central PMCID: PMCPMC10880292.
  10. Negahdaripour M. COVID-19 Vaccine Global Access Is an Urgency. Iran J Med Sci. 2021;46:79-80. doi: 10.30476/ijms.2021.47336. PubMed PMID: 33753951; PubMed Central PMCID: PMCPMC7966931.
آمار
تعداد مشاهده مقاله: 11
تعداد دریافت فایل اصل مقاله: 7


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب